Dexamethasone-Induced Ocular Hypertension in Mice

Effects of Myocilin and Route of Administration

Gaurang C. Patel, Tien N. Phan, Prabhavathi Maddineni, Ramesh B. Kasetti, John Cameron Millar, Abbot Clark, Gulab Zode

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead to iatrogenic glaucoma and permanent vision loss. An appropriate mouse model can help us understand precise molecular mechanisms and etiology of GC-induced OHT. We therefore developed a novel, simple, and reproducible mouse model of GC-induced OHT. GC-induced myocilin expression in the trabecular meshwork (TM) has been suggested to play an important role in GC-induced OHT. We further determined whether myocilin contributes to GC-OHT. C57BL/6J mice received weekly periocular conjunctival fornix injections of a dexamethasone-21-acetate (DEX-Ac) formulation. Intraocular pressure (IOP) elevation was relatively rapid and significant, and correlated with reduced conventional outflow facility. Nighttime IOPs were higher in ocular hypertensive eyes compared to daytime IOPs. DEX-Ac treatment led to increased expression of fibronectin, collagen I, and α-smooth muscle actin in the TM in mouse eyes. No changes in body weight indicated no systemic toxicity associated with DEX-Ac treatment. Wild-type mice showed increased myocilin expression in the TM on DEX-Ac treatment. Both wild-type and Myoc−/− mice had equivalent and significantly elevated IOP with DEX-Ac treatment every week. In conclusion, our mouse model mimics many aspects of GC-induced OHT in humans, and we further demonstrate that myocilin does not play a major role in DEX-induced OHT in mice.

Original languageEnglish
Pages (from-to)713-723
Number of pages11
JournalAmerican Journal of Pathology
Volume187
Issue number4
DOIs
StatePublished - 1 Apr 2017

Fingerprint

Ocular Hypertension
Dexamethasone
Glucocorticoids
Trabecular Meshwork
Intraocular Pressure
Therapeutics
Body Weight Changes
trabecular meshwork-induced glucocorticoid response protein
Inbred C57BL Mouse
Fibronectins
Glaucoma
Smooth Muscle
Actins
Collagen
dexamethasone acetate
Injections

Cite this

Patel, Gaurang C. ; Phan, Tien N. ; Maddineni, Prabhavathi ; Kasetti, Ramesh B. ; Millar, John Cameron ; Clark, Abbot ; Zode, Gulab. / Dexamethasone-Induced Ocular Hypertension in Mice : Effects of Myocilin and Route of Administration. In: American Journal of Pathology. 2017 ; Vol. 187, No. 4. pp. 713-723.
@article{265092dc465a4728bcf8dc6ec3384abd,
title = "Dexamethasone-Induced Ocular Hypertension in Mice: Effects of Myocilin and Route of Administration",
abstract = "Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead to iatrogenic glaucoma and permanent vision loss. An appropriate mouse model can help us understand precise molecular mechanisms and etiology of GC-induced OHT. We therefore developed a novel, simple, and reproducible mouse model of GC-induced OHT. GC-induced myocilin expression in the trabecular meshwork (TM) has been suggested to play an important role in GC-induced OHT. We further determined whether myocilin contributes to GC-OHT. C57BL/6J mice received weekly periocular conjunctival fornix injections of a dexamethasone-21-acetate (DEX-Ac) formulation. Intraocular pressure (IOP) elevation was relatively rapid and significant, and correlated with reduced conventional outflow facility. Nighttime IOPs were higher in ocular hypertensive eyes compared to daytime IOPs. DEX-Ac treatment led to increased expression of fibronectin, collagen I, and α-smooth muscle actin in the TM in mouse eyes. No changes in body weight indicated no systemic toxicity associated with DEX-Ac treatment. Wild-type mice showed increased myocilin expression in the TM on DEX-Ac treatment. Both wild-type and Myoc−/− mice had equivalent and significantly elevated IOP with DEX-Ac treatment every week. In conclusion, our mouse model mimics many aspects of GC-induced OHT in humans, and we further demonstrate that myocilin does not play a major role in DEX-induced OHT in mice.",
author = "Patel, {Gaurang C.} and Phan, {Tien N.} and Prabhavathi Maddineni and Kasetti, {Ramesh B.} and Millar, {John Cameron} and Abbot Clark and Gulab Zode",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.ajpath.2016.12.003",
language = "English",
volume = "187",
pages = "713--723",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

Dexamethasone-Induced Ocular Hypertension in Mice : Effects of Myocilin and Route of Administration. / Patel, Gaurang C.; Phan, Tien N.; Maddineni, Prabhavathi; Kasetti, Ramesh B.; Millar, John Cameron; Clark, Abbot; Zode, Gulab.

In: American Journal of Pathology, Vol. 187, No. 4, 01.04.2017, p. 713-723.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dexamethasone-Induced Ocular Hypertension in Mice

T2 - Effects of Myocilin and Route of Administration

AU - Patel, Gaurang C.

AU - Phan, Tien N.

AU - Maddineni, Prabhavathi

AU - Kasetti, Ramesh B.

AU - Millar, John Cameron

AU - Clark, Abbot

AU - Zode, Gulab

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead to iatrogenic glaucoma and permanent vision loss. An appropriate mouse model can help us understand precise molecular mechanisms and etiology of GC-induced OHT. We therefore developed a novel, simple, and reproducible mouse model of GC-induced OHT. GC-induced myocilin expression in the trabecular meshwork (TM) has been suggested to play an important role in GC-induced OHT. We further determined whether myocilin contributes to GC-OHT. C57BL/6J mice received weekly periocular conjunctival fornix injections of a dexamethasone-21-acetate (DEX-Ac) formulation. Intraocular pressure (IOP) elevation was relatively rapid and significant, and correlated with reduced conventional outflow facility. Nighttime IOPs were higher in ocular hypertensive eyes compared to daytime IOPs. DEX-Ac treatment led to increased expression of fibronectin, collagen I, and α-smooth muscle actin in the TM in mouse eyes. No changes in body weight indicated no systemic toxicity associated with DEX-Ac treatment. Wild-type mice showed increased myocilin expression in the TM on DEX-Ac treatment. Both wild-type and Myoc−/− mice had equivalent and significantly elevated IOP with DEX-Ac treatment every week. In conclusion, our mouse model mimics many aspects of GC-induced OHT in humans, and we further demonstrate that myocilin does not play a major role in DEX-induced OHT in mice.

AB - Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead to iatrogenic glaucoma and permanent vision loss. An appropriate mouse model can help us understand precise molecular mechanisms and etiology of GC-induced OHT. We therefore developed a novel, simple, and reproducible mouse model of GC-induced OHT. GC-induced myocilin expression in the trabecular meshwork (TM) has been suggested to play an important role in GC-induced OHT. We further determined whether myocilin contributes to GC-OHT. C57BL/6J mice received weekly periocular conjunctival fornix injections of a dexamethasone-21-acetate (DEX-Ac) formulation. Intraocular pressure (IOP) elevation was relatively rapid and significant, and correlated with reduced conventional outflow facility. Nighttime IOPs were higher in ocular hypertensive eyes compared to daytime IOPs. DEX-Ac treatment led to increased expression of fibronectin, collagen I, and α-smooth muscle actin in the TM in mouse eyes. No changes in body weight indicated no systemic toxicity associated with DEX-Ac treatment. Wild-type mice showed increased myocilin expression in the TM on DEX-Ac treatment. Both wild-type and Myoc−/− mice had equivalent and significantly elevated IOP with DEX-Ac treatment every week. In conclusion, our mouse model mimics many aspects of GC-induced OHT in humans, and we further demonstrate that myocilin does not play a major role in DEX-induced OHT in mice.

UR - http://www.scopus.com/inward/record.url?scp=85016054020&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2016.12.003

DO - 10.1016/j.ajpath.2016.12.003

M3 - Article

VL - 187

SP - 713

EP - 723

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -